Accessibility Menu
Pharmadrug logo

Pharmadrug(OTC) LMLLF

Market Cap$744.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-98%
1 Year-36%
1 Month-35%
$0.01
+3.70%
+0.00Today
Pharmadrug last closing stock price
MetricPriceDate
Last closeUSD 0.012026-09-04
Pharmadrug stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.91%USD 0.012026-08-28
1 month-35.47%USD 0.012026-08-05
3 month-36.93%USD 0.012026-06-04
Year to date-37.64%USD 0.012025-12-31
1 year-36.21%USD 0.012025-09-03
3 year-84.21%USD 0.042023-09-01
5 year-98.02%USD 0.282021-09-03
Since inception-99.74%USD 2.152018-08-30

Pharmadrug Financials at a Glance

Market Cap

$744.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$641.48K

EPS (TTM)

-$0.00

P/E Ratio

-1.50

Dividend

$0.00

Beta (Volatility)

-0.74 (Low)

Price

$0.01

Volume

285

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

May 21, 2026

LMLLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pharmadrug

Pharmadrug Inc. is a specialized pharmaceutical company focused on the exploration, development, and commercialization of controlled substances and naturally derived therapeutic agents. The company is actively involved in importing and distributing medical cannabis across Germany and the European Union, while also researching innovative compounds like psychedelics and cannabis.

Products and Services
  • Development of novel compounds, including psychedelics and cannabis
  • Import and distribution of medical cannabis to pharmacies
  • Research initiatives on functional and psilocybin mushrooms
Growth Outlook
  • Partnership with the University of Michigan to explore DMT's therapeutic potential
  • Clinical trial agreement with Johns Hopkins University for DMT studies
  • Expansion of medical cannabis distribution in the European market
Financial Highlights
  • Recent quarterly net income of -$187,222, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating a focus on future growth
  • Cash and short-term investments totaling $388,709, providing operational liquidity
Pharmadrug Inc. operates in a rapidly evolving sector, with a strong emphasis on research and development. The company's strategic partnerships with leading institutions enhance its innovative capabilities, particularly in the field of psychedelics and cannabis. Despite recent financial challenges, the focus on expanding distribution channels and developing new therapeutic agents positions Pharmadrug for potential growth in the burgeoning medical cannabis market. The company's commitment to exploring the benefits of natural remedies and controlled substances reflects a forward-thinking approach in the healthcare industry.
AI Generated • Aug 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Robert J. Steen, MBA

Website

www.pharmadrug.co

Headquarters

Toronto, ON M5K 1H1, CA

LMLLF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

37.95%

Return on Capital

N/A

Return on Assets

-85.23%

Earnings Yield

-66.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$744.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

134.21M

Volume

285

Avg. Volume

16.71K

Financials (TTM)

Gross Profit

-CA$37.72K

Operating Income

-CA$202.34K

EBITDA

-CA$164.63K

Operating Cash Flow

-CA$89.72K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$89.72K

Cash & ST Invst.

CA$23.06K

Total Debt

CA$1.81M

Pharmadrug Performance Analysis

Pharmadrug annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Pharmadrug sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Pharmadrug annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.106.7%
20232023-12-31CAD -0.1771.0%
20242024-12-31CAD -0.01-96.8%
20252025-12-31CAD -0.00-55.4%
Pharmadrug sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-42.9%
Q42025-12-31N/A
Q12026-03-31-40.0%
Q22026-06-30-42.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$744.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$82.77K

N/A

Employees

9

N/A

Net Income

-CA$243.74K

-235.6%

EBITDA

-CA$9.35K

+47.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$23.06K

+30.2%

Total Debt

CA$1.81M

+26.0%

Accounts Receivable

CA$0.00

-100.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$1.81M

+26.0%

Return on Assets

-85.23%

N/A

Return on Invested Capital

15.80%

N/A

Free Cash Flow

-CA$25.71K

-35216.3%

Operating Cash Flow

-CA$25.71K

-35216.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RDDTFRadient Technologies Inc.
$0.00+0.00%
CPMDCannaPharmaRX, Inc.
$0.00+0.00%
TGIFF1933 Industries Inc.
$0.00-4.44%
RAFARafarma Pharmaceuticals, Inc.
$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About LMLLF

What is the current price of Pharmadrug?

Pharmadrug is trading at $0.01 per share.

What is the 52-week range for Pharmadrug?

Over the past 52 weeks, Pharmadrug has traded between $0.00 and $0.02.

How much debt does Pharmadrug have?

As of the most recent reporting period, Pharmadrug reported total debt of CA$1.20M.

How much cash does Pharmadrug have on hand?

Pharmadrug reported CA$19.99K in cash and cash equivalents in its most recent financial results.

What is Pharmadrug’s dividend yield?

Pharmadrug does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services